Key result
Long-dwell icodextrin solution maintained reasonable cardiac structure and function over 24 months in incident-automated peritoneal dialysis patients, with no major differences compared to glucose-based solutions.
Why the study?
Does icodextrin solution improve or maintain cardiac structure and function compared to glucose-based solution in incident-automated peritoneal dialysis patients?
RCT (n=43)
Open-label
Computer-generated block randomization
No
Does icodextrin solution improve or maintain cardiac structure and function compared to glucose-based solution in incident-automated peritoneal dialysis patients?
Both long-dwell icodextrin and glucose-based peritoneal dialysis solutions maintain stable cardiac structure and function over 2 years in incident automated peritoneal dialysis patients.
Either solution maintains cardiac stability over 2 years in incident APD; extends RCT evidence of no cardiac superiority for icodextrin.
BACKGROUND: This study aimed to evaluate the longitudinal changes in cardiac structure and function in incident-automated peritoneal dialysis (APD) patients. METHODS: We conducted a 2-year prospective, randomized, open-label, parallel-group study to compare the efficacy of icodextrin solution versus glucose-based solution. Echocardiography was performed at baseline, 1 and 2 years. Echocardiographic parameters over 2 years were evaluated for each group, using the Friedman test. Generalized linear regression analysis was used to test the associations between baseline clinical variables and echocardiographic changes, and a multivariate model was used to analyze cardiac function between the two groups. RESULTS: A total of 43 APD patients were enrolled in the beginning of this study. Twenty patients in the icodextrin group (ICO) and 18 patients in the glucose group (GLU) completed the study. In left ventricular (LV) systolic function measurements, ejection fraction (EF) increased significantly in the GLU group. Measurements of LV diastolic function and septal early mitral annulus velocity (EMV) increased significantly from baseline to 24-months in the ICO group (5.43-5.51 ms). The GLU group showed a significant decrease in peak early diastolic velocity (EDV) (70.67-68.25 cm/s), but a significant increase in septal EMV (5.94-7.57 ms) from baseline to 24-months. No significant association was found between the baseline clinical variables and echocardiographic changes within 24 months in the generalized linear regression analysis. Multivariate models were used to investigate changes in the four primary endpoints, namely, myocardial performance index (MPI), left ventricular ejection fraction (LVEF), deceleration time (DT), and E/e' ratio. These primary endpoints show no significant association with the baseline values in both the ICO and GLU groups. CONCLUSION: The present study demonstrates that long-dwell icodextrin solution can maintain reasonable cardiac structure and function in incident-APD patients. TRIAL REGISTRATION: ISRCTN14931270 (retrospectively registered on 23/03/2018).
No takes yet. Share an insight, caveat, or question.
Chen et al. (2018) conducted an RCT in Incident-automated peritoneal dialysis (APD) in stage 5 chronic kidney disease (n=43). Icodextrin solution vs. Glucose-based PD solution (1.36%, 2.27%, and 3.86%) was evaluated on Changes in myocardial performance index (MPI), left ventricular ejection fraction (LVEF), deceleration time (DT), and E/e′ ratio at 24 months. Long-dwell icodextrin solution maintained reasonable cardiac structure and function over 24 months in incident-automated peritoneal dialysis patients, with no major differences compared to glucose-based solutions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: